Screener
Dianthus Therapeutics DNTH Operating Income
Operating Income at other companies
Other financials
Where this comes from
Reported directly by Dianthus Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:OperatingIncomeLoss.
The source filing: Dianthus Therapeutics’s 10-Q, filed May 5, 2026.
- Filed
- May 5, 2026, 4:06 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001690585-26-000022
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Research and development | 34,528 | 27,003 |
| General and administrative | 12,468 | 7,337 |
| Total operating expenses | 46,996 | 34,340 |
| Loss from operations | (46,533) | (33,177) |
| Other income/(expense): | ||
| Interest and investment income | 6,265 | 3,791 |
| Loss on investment in former related party | (302) | (5) |
| Loss on currency exchange, net | (15) | (22) |
Item 1. Condensed Consolidated Financial Statements (Unaudited)
FAQ
- What is Dianthus Therapeutics's operating income?
- Dianthus Therapeutics (DNTH) reported operating income of -$46.53M in Q1 2026.
- How has Dianthus Therapeutics's operating income changed year-over-year?
- Dianthus Therapeutics's operating income decreased by 40.3% year-over-year, from -$33.18M to -$46.53M.
- What is the long-term trend for Dianthus Therapeutics's operating income?
- Over 3 years (2021 to 2024), Dianthus Therapeutics's operating income has grown at a 10.9% compound annual growth rate (CAGR), from -$74.69M to -$101.86M.
- What does operating income mean?
- Gross profit minus all operating expenses (SG&A, R&D, D&A). Measures the profit from core business operations before interest, taxes, and non-operating items.
Ask your AI about Dianthus Therapeutics's operating income.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude